Treatment
Ruxolitinib clinical trials
We’re tracking 101 recruiting studies that include Ruxolitinib, each written for real people, not researchers, below.
Recruiting studies
- NCT04116502RecruitingPhase 3
Ruxolitinib versus standard treatments for high-risk polycythemia vera
This Phase 3 study compares ruxolitinib against hydroxycarbamide or interferon as the first treatment for people with high-risk polycythemia vera. It aims to see which option works better to reduce disease-related problems and complications.
AberdeenAges 18 years+ - NCT04282187RecruitingPhase 2
Decitabine plus targeted drugs for advanced blood cancer blast phase
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
Seattle, WashingtonAges 18 years+ - NCT04644211RecruitingPhase 2
Ruxolitinib for symptom control in certain blood cancer types
This Phase 2 study tests ruxolitinib (a targeted medicine) in people with essential thrombocythemia or polycythemia vera who still have troublesome symptoms. It aims to see whether it can reduce symptoms by changing disease activity and blood-related inflammation.
Boston, MassachusettsAges 18 years+ - NCT04744116RecruitingEarly Phase 1
Cord blood cell therapy added to ruxolitinib for steroid-resistant GVHD
This trial studies whether adding cord-blood–derived cells to ruxolitinib can improve steroid-resistant acute graft-versus-host disease (GVHD) affecting the lower gut or liver. It’s meant for people who are not getting better (or are worsening) despite adequate steroid treatment.
Houston, TexasAges 12–80 - NCT05010005RecruitingPhase 1
Testing ruxolitinib plus duvelisib for relapsed T-cell lymphoma
This Phase 1 study tests how safe and effective ruxolitinib plus duvelisib are in adults with certain types of mature T-cell lymphomas. You may be considered if your lymphoma has come back or worsened despite prior treatment, and the study checks whether this pill combination can help control the disease.
Miami, FloridaAges 18 years+ - NCT05037760RecruitingPhase 2
Elritercept alone or with ruxolitinib for myelofibrosis
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
Concord, New South WalesAges 18 years+ - NCT05371964RecruitingPhase 1
Imetelstat plus ruxolitinib for myelofibrosis patients
This Phase 1 study tests whether imetelstat combined with ruxolitinib is safe and may improve disease activity in people with myelofibrosis. It is aimed at people who need symptom control and may be taking (or considered for) ruxolitinib.
Duarte, CaliforniaAges 18 years+ - NCT05398809RecruitingPhase 2
Ruxolitinib for hair regrowth in APECED-related alopecia areata
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
Bethesda, MarylandAges 12–75 - NCT05592015RecruitingPhase 2
Ruxolitinib for T-cell large granular leukemia
This Phase 2 study tests ruxolitinib, a targeted medicine, to improve outcomes in T-cell large granular lymphocytic leukemia (T-LGLL). It is for people whose disease is causing symptoms or who have already tried other treatment, with specific blood, infection, and medication requirements.
Boston, MassachusettsAges 18 years+ - NCT05745714RecruitingPhase 1/Phase 2
Targeted triple-combination treatment for children with relapsed blood cancers
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
ViennaAges 1–21 - NCT05762640RecruitingPhase 2
Ruxolitinib for first-time treatment of primary HLH
This Phase 2 study tests ruxolitinib as a first treatment for primary HLH, a rare, sometimes life-threatening immune overreaction. It may help calm the immune system and improve symptoms by blocking key immune signals.
Paris, Île-de-France RegionAges Up to 22 years - NCT05870475RecruitingPhase 2
Interferon plus ruxolitinib for hydroxyurea-resistant polycythemia vera
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
TianjinAges 18 years+ - NCT06008275RecruitingEarly Phase 1
Neratinib and ruxolitinib for metastatic triple-negative breast cancer
This early-phase trial tests a combination of two targeted drugs, neratinib and ruxolitinib, for people with metastatic triple-negative breast cancer who have already had standard chemotherapy. The goal is to see if the combination is safe and effective.
Dallas, TexasAges 18 years+ - NCT06008808RecruitingPhase 1
Ruxolitinib and abatacept to prevent GVHD after haplo transplant
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
St Louis, MissouriAges 18 years+ - NCT06034002RecruitingPhase 1
Study of INCA033989 for myeloproliferative neoplasms
This trial tests a new drug, INCA033989, alone or with ruxolitinib for people with certain blood cancers called myeloproliferative neoplasms (MPNs). It may help those with a specific genetic change (CALR mutation) who have not had success with other treatments.
Duarte, CaliforniaAges 18 years+ - NCT06128070RecruitingPhase 2
Preventing GVHD after stem cell transplant for leukemia
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
Duarte, CaliforniaAges 2–22 - NCT06225310RecruitingPhase 1
New combo for relapsed/refractory multiple myeloma
This trial tests a three-drug combination (selinexor, ruxolitinib, and methylprednisolone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new combination can help control the cancer.
West Hollywood, CaliforniaAges Any age - NCT06233110RecruitingPhase 1
Ruxolitinib and fostamatinib for steroid-resistant chronic GVHD
This study tests two drugs, ruxolitinib and fostamatinib, together for people with chronic graft-versus-host disease (GVHD) that hasn't responded well to steroids. The goal is to see if this combination can better control GVHD.
Durham, North CarolinaAges 18–80 - NCT06259669Recruiting
Studying eczema cream safety during pregnancy
This study compares the health of mothers and their babies in two groups: women with eczema who used ruxolitinib cream during pregnancy and those who did not. It aims to see if the cream is safe for both mother and child.
Morrisville, North CarolinaAges 15–50 - NCT06261021RecruitingPhase 2
Ruxolitinib cream for discoid lupus study
This trial tests a cream (ruxolitinib) on discoid lupus skin lesions. It aims to see if the cream can reduce DLE symptoms in adults.
Fredericton, New BrunswickAges 18 years+ - NCT06291987RecruitingPhase 1
Ivosidenib with ruxolitinib for advanced MPN with IDH1 mutation
This trial tests a combination of two targeted drugs, ivosidenib and ruxolitinib, for people with advanced myeloproliferative neoplasms (MPNs) that have an IDH1 gene mutation. The goal is to see if this treatment can help control the disease.
Chicago, IllinoisAges 18 years+ - NCT06345495RecruitingPhase 2
High-dose ruxolitinib and stem cell transplant for enlarged spleen in myelofibrosis
This trial tests a higher dose of ruxolitinib before a stem cell transplant for people with myelofibrosis who have an enlarged spleen. It aims to see if this approach helps the transplant work better.
Houston, TexasAges 18–75 - NCT06536166RecruitingPhase 2
Ruxolitinib for Inclusion Body Myositis
This trial tests the drug ruxolitinib (a JAK inhibitor) for people with inclusion body myositis (IBM), a progressive muscle disease. It aims to see if ruxolitinib can help slow muscle weakness and improve function.
Angers, FranceAges 45 years+ - NCT06616155RecruitingPhase 1/Phase 2
Ruxolitinib and Enzalutamide for Resistant Prostate Cancer
This trial tests two drugs—ruxolitinib and enzalutamide—together to see if they can help men whose prostate cancer has spread and stopped responding to abiraterone. It is for those whose cancer grew quickly on abiraterone.
Chicago, IllinoisAges 18 years+
Common questions
- Are there clinical trials studying Ruxolitinib?
- Yes. Clin2 currently lists 101 recruiting studies that include Ruxolitinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ruxolitinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ruxolitinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ruxolitinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.